Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model | Zendy

Razieh Kebriaei | Zendy; Katherine L. Lev | Zendy; Kyle Stamper | Zendy; Susan M. Lehman | Zendy; Sandra Morales | Zendy; Michael J. Rybak | Zendy

Open Access

Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model

Author(s) -

Razieh Kebriaei,

Katherine L. Lev,

Kyle Stamper,

Susan M. Lehman,

Sandra Morales,

Michael J. Rybak

Publication year - 2020

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01863-20

Subject(s) - bacteriophage , pharmacodynamics , microbiology and biotechnology , antibiotics , pharmacokinetics , staphylococcus aureus , biology , in vivo , in vitro , virology , pharmacology , bacteria , escherichia coli , genetics , gene

This study aimed to test the efficacy of bacteriophage-antibiotic combinations (BACs) in vitro in 24-h time-kill settings and in ex vivo simulated endocardial vegetation (SEV) pharmacokinetic/pharmacodynamic models for 96 h. BACs prevented the development of bacteriophage resistance, while some bacteriophage resistance emerged in bacteriophage-alone treatments. In addition, BACs resulted in an enhancement of bacterial eradication in SEV models. Our findings support the potential activity of BAC therapy for combating serious methicillin-resistant Staphylococcus aureus (MRSA) infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research